Vanguard Group Inc Crinetics Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

$6.44 Trillion
Q3 2025

A detailed history of Vanguard Group Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 9,170,129 shares of CRNX stock, worth $399 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

9,170,129

Previous 9,256,132 0.93%

Holding current value

$399 Million

Previous $266 Million 43.47%

% of portfolio

0.01%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	SELL	$26.85 - $45.91 $2.31 Million - $3.95 Million	-86,003 Reduced 0.93%	9,170,129 $382 Million
Q2 2025 Aug 11, 2025	SELL	$25.56 - $33.76 $1.42 Million - $1.87 Million	-55,468 Reduced 0.6%	9,256,132 $266 Million
Q1 2025 May 09, 2025	BUY	$32.3 - $53.15 $7.18 Million - $11.8 Million	222,209 Added 2.44%	9,311,600 $312 Million
Q4 2024 Feb 11, 2025	BUY	$50.66 - $60.69 $142 Million - $170 Million	2,801,736 Added 44.56%	9,089,391 $465 Million
Q3 2024 Nov 13, 2024	BUY	$43.83 - $54.98 $77.7 Million - $97.5 Million	1,773,177 Added 39.28%	6,287,655 $321 Million
Q2 2024 Aug 13, 2024	BUY	$42.12 - $51.91 $39.6 Million - $48.8 Million	939,402 Added 26.28%	4,514,478 $202 Million
Q1 2024 May 10, 2024	BUY	$34.76 - $46.81 $2.52 Million - $3.4 Million	72,624 Added 2.07%	3,575,076 $167 Million
Q4 2023 Feb 14, 2024	BUY	$25.62 - $37.07 $2.44 Million - $3.54 Million	95,417 Added 2.8%	3,502,452 $125 Million
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $10.8 Million - $20.6 Million	674,301 Added 24.67%	3,407,035 $101 Million
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $624,040 - $936,259	39,672 Added 1.47%	2,732,734 $49.2 Million
Q1 2023 May 15, 2023	BUY	$15.31 - $21.1 $4.7 Million - $6.47 Million	306,675 Added 12.85%	2,693,062 $43.3 Million
Q4 2022 Feb 10, 2023	BUY	$15.49 - $19.05 $460,672 - $566,547	29,740 Added 1.26%	2,386,387 $43.7 Million
Q3 2022 Nov 14, 2022	SELL	$18.11 - $22.37 $1.59 Million - $1.97 Million	-87,867 Reduced 3.59%	2,356,647 $46.3 Million
Q2 2022 Aug 12, 2022	BUY	$16.49 - $27.64 $5.69 Million - $9.54 Million	345,201 Added 16.44%	2,444,514 $45.6 Million
Q1 2022 May 13, 2022	BUY	$17.15 - $28.31 $41,417 - $68,368	2,415 Added 0.12%	2,099,313 $46.1 Million
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $8.15 Million - $12 Million	421,017 Added 25.12%	2,096,898 $59.6 Million
Q3 2021 Nov 12, 2021	BUY	$16.88 - $25.23 $2.92 Million - $4.37 Million	173,044 Added 11.51%	1,675,881 $35.3 Million
Q2 2021 Aug 13, 2021	BUY	$15.9 - $21.15 $23.9 Million - $31.8 Million	1,502,837 New	1,502,837 $28.3 Million

Others Institutions Holding CRNX

# of Institutions

247

Shares Held

92.8M

Call Options Held

1.02M

Put Options Held

204K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.34B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Crinetics Pharmaceuticals, Inc. Transaction History